SESSION 2 The Future of Standard 20/7E and Future Pharma Committee Activity Areas





Anthony (TJ) Rizzo Chief Commercial Officer Cold Chain Technologies, Inc.



Bryan Cardis Associate Sr. Consultant Engineer, Eli Lilly and Company



Arminda Montero Associate Director, Global Supply Chain Quality, AbbVie Inc.



Bill Mayer Director of Research and Development, Pelican Biothermal



Carolyn Williamson President, Parenteral Supply Chain

SESSION 2 The Future of Standard 20/7E



STD-0020:

- Design and qualification process that provides the structure and path to design, test, verify a specific Insulated Shipping Container (ISC) for use.
- Sets minimum requirements for qualifying insulated shippers

STD-7E:

- Testing Standard for Thermal Transport Packaging Used in Parcel Delivery System Shipment.
- Includes heat and cold profiles developed from data gathered in real world transport.
- Intended to address issue of gauging ISC performance of designs across manufacturers by offering a standard profile for performance testing.

ISTA Certified - Transport Lab vs Thermal Lab:

- Transport Testing Laboratory certification assures a laboratory is properly equipped to conduct ISTA pre transit package performance testing.
- Thermal Testing Lab certification enables compliance with ISTA Standard 20. A certified lab utilizing this
 process, in conjunction with thermal profile ISTA 7E, can qualify packaging solutions as 'Certified to ISTA
 Standard 20'.
 - Requires training and certification of lab personnel
 - Requires audit with initial certification and re-certification







ISTA Standard 20/7E General Overview

• Review and solicit feedback on one possible reorganization of Standard 20

Identified Key Areas for Future Improvement & wider adoption:

- Accessibility (\$'s / time /availability)
- Flexibility (requirements of program and standard)
- Relevance & Intent (currently required? Restructuring and standard updates)

Voice of Stakeholders:

- Packaging supplier perspective Scott Dyvig/Bill Mayer/TJ Rizzo
- Auditor perspective Carolyn Williamson
- End user perspective Arminda & Bryan?
- Independent test labs & other groups

SESSION 2 The Future of Standard 20/7E



Î	 + Package -Allows for ISTA certification mark to be used on package -Requires full access and compliances with the levels below -ISTA to provide qualified reviewers of submitted data to allow certification of the submitted package 	
		nose without existing proper personnel training program. Adds additional layer of those who already have an existing valid training system in place
Investment Level (time & \$)	+ Lab certification qual	s value to those without existing lab accreditation (i.e. ISO 17025 etc.) or proper ity system. Adds additional layer of scrutiny/accreditation to those who already have kisting valid system in place
	+ Digital platform access	 Proposed adding a digital platform that could auto-populate documentation and act as a storage location. Could also serve as a platform to allow sharing of documentation Standard can be executed and documented properly in conjunction with an existing quality system and training program
	+ Template and appendix access	 Allows access to the ISTA approved templates and appendices for consistent documentation and testing practices associated with the standard Standard can be executed and documented properly in conjunction with an existing quality system and training program
	Standard 20 & 7E base document	 Available to all ISTA members (with annual dues) and for minimal purchase cost for non-members (broad access) Standard can be reviewed and followed

Open audience feedback and discussion:

- Pros & cons
- Alternative reorganization ideas?
- Would you use and promote Standard 20?

Next Steps:

• Vote if in favor or not of a reorganization of Standard 20 & full technical review

Committee Activity Overview

The ISTA Pharma Committee will sponsor different types of activities including:

- Best Practice Guidelines
- Short Technical Papers
- Benchmarking Discussion Groups
- Presentations
- Articles
- Data Sharing
- Technology Evaluations
- Industry Conference Discussions

Best Practice Guidance Overview

- The intent of the developed guidelines are to establish an **aligned industry best practices** for key industry topics.
- The goal is to have **principles described in this guideline be adopted by the entire pharmaceutical supply chain**, including manufacturers, suppliers of passive thermal packaging, logistic service providers, carriers, wholesalers, distributors, specialty pharmacies, and any other interested party.
- The level of detail beyond the suggested industry best practice is the decision of the primary stakeholders of the temperature-sensitive product, based on risk acceptance.
- While there are other guideline documents available in the industry, the ISTA Pharma Committee aims to provide users with a how to guide to achieve success on important industry topics but allow users to work within their own internal procedures.
- The goal for any activity from the ISTA Pharma Committee is to make the **content easily accessible to the industry as a whole and will be free of charge** when possible.

Committee Activity Status

<u>Completed</u>

- 1. "PCG-01: Reusable Passive Thermal Packaging System Best Practice Guideline" published August 2018
- 2. "PCG-02: Passive Thermal Packaging System Operational Qualification Best Practice Guideline" – published November 2020

In Process

- 1. PCG-00: Glossary of Terms Available for Peer Review in March 2022
- 2. PCG-03: Performance Qualification/Verification Best Practice Guideline (final title to be determined) Available for Peer Review in March 2022
- 3. PCG-04: Ambient Temperature Profile Best Practice Guideline (final title to be determined) Available for Peer Review in March/April 2022

SESSION 2 Future Pharma Committee Activity Areas



Future Topics of Interest

- Design Qualification
- Risk Assessment associated with Selecting and/or implementing temperature-controlled packaging
- Thermal Modeling
- Lane Qualification
- Sustainability
- Thermal Blankets/Covers
- RFP/URS Development
- Real-time monitoring
- Mechanical testing best practices: Bulk versus Parcel and Single Use versus Reusable
- Total Cost of Ownership
- Continuous Monitoring Strategies

- Qualification of Active ULD Solutions
- Temperature Monitoring Strategies
- Validation of Refrigerated trailers
- Ambient temperature lane data capture project
- Shipper Orientation
- Gene Therapy Strategy
- Ocean Freight
- Dry Ice Shippers
- Anti-counterfeiting and Product Security
- Long duration (>7 day) passive PCM and dry ice shippers
- Clinical, phase appropriateness testing strategy

SESSION 2 Future Pharma Committee Activity Areas



2020 Next Activity Vote Review

• 70 Responses total

• Top 6 Topics

- Performance
 Qualification/Verification
- Ambient Temperature Profile Creation
- Sustainability
- Risk Assessment in Selecting Temperature-Controlled Packaging
- Design Qualification
- Mechanical Testing Best Practices

• The Next 4

- Thermal Modeling
- Dry Ice Shippers
- Continuous Monitoring Strategies
- Total Cost of Ownership

Торіс	✓↓ Votes
Performance Qualification/Verification	
Ambient Temperature Profile Creation	
Sustainability	
Risk Assessment associated with Selecting temperature-controlled packaging	
Design Qualification	
Mechanical testing best practices: Bulk versus Parcel and Single Use versus Reusable	
Thermal Modeling	
Dry Ice Shippers	
Continuous Monitoring Strategies	
Total Cost of Ownership	
Lane Qualification	12
Temperature Monitoring Strategies	11
Long duration (>7 day) passive PCM and dry ice shippers	11
Gene Therapy Strategy	11
Ambient Temperature Profile Comparison Methodology	
Shipper Orientation	
Real-time monitoring	
Validation of Refrigerated trailers	
Ambient temperature lane data capture project	
Ocean Freight	
Thermal Blankets/Covers	
Clinical, phase appropriateness testing strategy	
Qualification of Active ULD Solutions	4
RFP/URS Development	3
Anti-counterfeiting and Product Security	3
Fuutre Topics	
Cell Therapy at (-196 Degree C)	
Shipping with 2-8C service lane assesment	
ISTA 7E and Standard 20 - current status and proposed updates	
Simulated distribution testing.	
What is the objective of this survey?	
Strategies for documenting controlled temperature shipping systems in health authority submissions	
Ecommerce. Evaluating performance of single item product shipping methods	
Grand Total	294



Items to Consider when Voting on the Next Topics

- •What do you think needs to be solved?
- •What specific areas do you think should be addressed?
- •What type of activity would address the need?
 - Best Practice Guidelines
 - Short Technical Papers
 - Benchmarking Discussion Groups
 - Presentations
 - Articles
 - Data Sharing
 - Technology Evaluations
 - Industry Conference Discussions

SESSION 2 Future Pharma Committee Activity Areas

Next Steps

- You will receive a link to vote please complete no later than February 22nd, 2022
- If you would like to join a specific project team or participate as an extended team member, please contact ISTA at <u>ista@ista.org</u> and include the Pharma Committee in the title.
- All new members will be added to the extended team and asked to provide peer review of all committee work.

We are looking for more involvement from all areas of the supply chain including:

Medicinal product manufacturers Suppliers of passive thermal packaging Active thermal solution/service providers Transportation monitoring solution providers Logistic service providers Wholesalers Distributors Specialty pharmacies Industry subject matter experts and any other interested party.

Expectations of Membership

- Show respect among their peers
- Gain support from their organization to dedicate time & resources to participate in the group's efforts
- Actively engage in the development of technical content by sharing their/their company's views on individual topics but not share confidential information
- Be available and willing to participate in conference calls and in-person meetings, both for the group as a whole and individual sub-groups as needed
- Solicit the participation of key individuals or other organizations in the industry as required
- Allow their name to be used in association with any guidance developed by the group for which they are an active participant based on company approval
- Refrain from all commercial activity
- Attend monthly ISTA Pharma Committee Meeting: Committee Chair, Committee Members, and Core Team.



Additional questions or comments?

Send them via email to:

webinar@ista.org

Calendar of Events

- February/March 2022: Peer review of current activity work
- March/April 2022: Committee Member Nominations
- April 11-13, 2022: ISTA Forum TransPack & TempPack in San Diego, CA
- Q2 2022: Kick of new committee activities
- Q3/Q4 2022: Virtual Technical Exchange

ista FORUM 2022 TransPack TempPack

APRIL 11-13 | SAN DIEGO, CALIFORNIA | MARRIOTT MARQUIS SAN DIEGO MARINA

PRE-FORUM TRAINING

April 11, 2022

- BioPharma Cold Chain 101
- URS to Operational Qualification
- Principles of Distribution Packaging
- Responsible Packaging by Design (RPbD) Training



Thank You